118288-08-7O=C(CS(=O)Cc1ccco1)NC/C=C\COc1cc(CN2CCCCC2)ccn1KMZQAVXSMUKBPD-DJWKRKHSSA-NLafutidine is an organic molecular entity.
118288-08-7、206449-93-6DTXSID0046434CHEMBL1742461CHEBI:31759Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory.
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
Lafutidine
DILI Positive
DOI:10.1016/j.drudis.2019.09.022
A - Alimentary tract and metabolism
QA - Alimentary tract and metabolism
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief.
Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood.
Usesrac Lafutidine is a second generation histamine H2-receptor antagonist. Lafutidine is used as an antiulcerative.
UsesSecond generation histamine H2-receptor antagonist. Antiulcerative.
No reaction records under the current filter.
Loading…
DefinitionChEBI: Lafutidine is an organic molecular entity.